The mid-regional proadrenomedullin (MR-proADM) was also found to predict all-cause mortality, heart failure hospitalization, and progression to NYHA class III–IV in moderate–severe AS patients, especially when combined with hsTnT or with NT-proBNP [137]. Here, NPPB is linked to aortic stenosis.